A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Biochaperone Combo
Humalog Mix25
Humalog
Lantus
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months
- HbA1c levels ≤ 9.0%
- Total insulin dose of < 1.2 U/kg/day
- Body mass index between 20.0 and 35.0 kg/m2 (both inclusive)
- Body weight ≤ 125.0 kg
- Fasting serum C-peptide ≤ 1 nmol/L
- Treated with a stable insulin regimen for ≥ 3 months prior to screening
Exclusion Criteria:
- Type 1 diabetes mellitus
- Known or suspected allergy to the trial products or related products
- Previous participation in this trial. Participation is defined as randomised
- Participation in any clinical trial within 3 months prior to this trial
- Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the Investigator considering the underlying disease
- Supine blood pressure at screening outside the range of 90-160 mmHg for systolic or 50-95 mmHg for diastolic and/or resting supine heart rate outside the range 50 -90 beats per minute. This exclusion criterion also pertains to subjects being on antihypertensives
- Use of GLP-1 receptor agonists or oral antidiabetic drugs (OADs) other than stable intake of metformin within 4 weeks prior to screening
- Women of child bearing potential, not willing to use contraceptive methods
Sites / Locations
- Profil Institut für Stoffwechselforschung GmbH
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Biochaperone Combo
Humalog Mix25
Humalog and Lantus
Arm Description
single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
Outcomes
Primary Outcome Measures
Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg)
Area under the glucose infusion rate curve from 12 hours to 30 hours
Secondary Outcome Measures
AUCGIR 0-last (mg/kg)
Area under the glucose infusion rate curve from 0 hours until the end of clamp
GIRmax (mg/kg/min)
Maximum glucose infusion rate
tGIRmax
Time to maximum glucose infusion rate
AUCLis 0-30h
Area under the insulin lispro plasma concentration time curve
AUCGla 0-30h
Area under the insulin glargine plasma concentration time curve
tmax Gla
Time to maximum insulin glargine plasma concentration
tmax Lis
Time to maximum insulin lispro plasma concentration
Adverse events
Number of adverse events
Hypoglycaemic episodes
Number of Hypoglycaemic episodes
Local tolerability
Number and intensity of injection site reactions
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02514850
Brief Title
A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
Official Title
A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Adocia
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a single centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over, euglycaemic clamp study in subjects with type 2 diabetes on stable insulin treatment. Each subject will be randomly allocated to a treatment sequence and will be administered single subcutaneous doses of 0.8 U/kg Biochaperone® Combo, 0.8 U/kg Humalog® Mix25 or simultaneous subcutaneous injections of 0.2 U/kg Humalog® and 0.6 U/kg Lantus® during three separate dosing visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Biochaperone Combo
Arm Type
Experimental
Arm Description
single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
Arm Title
Humalog Mix25
Arm Type
Active Comparator
Arm Description
single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
Arm Title
Humalog and Lantus
Arm Type
Active Comparator
Arm Description
simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
Intervention Type
Drug
Intervention Name(s)
Biochaperone Combo
Intervention Description
Injection of BioChaperone Combo
Intervention Type
Drug
Intervention Name(s)
Humalog Mix25
Intervention Description
Injection of Humalog Mix25
Intervention Type
Drug
Intervention Name(s)
Humalog
Intervention Description
Injection of Humalog
Intervention Type
Drug
Intervention Name(s)
Lantus
Intervention Description
Injection of Lantus
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Injection of saline 0.9% solution
Primary Outcome Measure Information:
Title
Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg)
Description
Area under the glucose infusion rate curve from 12 hours to 30 hours
Time Frame
from 12h to 30 hours
Secondary Outcome Measure Information:
Title
AUCGIR 0-last (mg/kg)
Description
Area under the glucose infusion rate curve from 0 hours until the end of clamp
Time Frame
Up to 30 hours
Title
GIRmax (mg/kg/min)
Description
Maximum glucose infusion rate
Time Frame
Up to 30 hours
Title
tGIRmax
Description
Time to maximum glucose infusion rate
Time Frame
Up to 30 hours
Title
AUCLis 0-30h
Description
Area under the insulin lispro plasma concentration time curve
Time Frame
Up to 30 hours
Title
AUCGla 0-30h
Description
Area under the insulin glargine plasma concentration time curve
Time Frame
Up to 30 hours
Title
tmax Gla
Description
Time to maximum insulin glargine plasma concentration
Time Frame
Up to 30 hours
Title
tmax Lis
Description
Time to maximum insulin lispro plasma concentration
Time Frame
Up to 30 hours
Title
Adverse events
Description
Number of adverse events
Time Frame
Up to 9 weeks
Title
Hypoglycaemic episodes
Description
Number of Hypoglycaemic episodes
Time Frame
Up to 9 weeks
Title
Local tolerability
Description
Number and intensity of injection site reactions
Time Frame
Up to 9 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months
HbA1c levels ≤ 9.0%
Total insulin dose of < 1.2 U/kg/day
Body mass index between 20.0 and 35.0 kg/m2 (both inclusive)
Body weight ≤ 125.0 kg
Fasting serum C-peptide ≤ 1 nmol/L
Treated with a stable insulin regimen for ≥ 3 months prior to screening
Exclusion Criteria:
Type 1 diabetes mellitus
Known or suspected allergy to the trial products or related products
Previous participation in this trial. Participation is defined as randomised
Participation in any clinical trial within 3 months prior to this trial
Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the Investigator considering the underlying disease
Supine blood pressure at screening outside the range of 90-160 mmHg for systolic or 50-95 mmHg for diastolic and/or resting supine heart rate outside the range 50 -90 beats per minute. This exclusion criterion also pertains to subjects being on antihypertensives
Use of GLP-1 receptor agonists or oral antidiabetic drugs (OADs) other than stable intake of metformin within 4 weeks prior to screening
Women of child bearing potential, not willing to use contraceptive methods
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ulrike Hövelmann, MD
Organizational Affiliation
Profil Institut Für Stoffwechselfforschung GmbH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Profil Institut für Stoffwechselforschung GmbH
City
Neuss
ZIP/Postal Code
41460
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
We'll reach out to this number within 24 hrs